46 results about "Liver transplantation" patented technology

The invention belongs to the field of liver cancer liver transplantation, and provides a liver cancer liver transplantation post-operation prognosis prediction system, which comprises a data acquisition module used for acquiring clinical data of a liver cancer patient from a plurality of data sources, including patient basic information, disease diagnosis information, drug use information and patient body function information; the data processing module is used for preprocessing the collected data, including data cleaning, missing value filling, data standardization and data integration, so as to ensure the quality and consistency of the data; by integrating multi-source data and combining advanced algorithms and models, accurate prediction of prognosis of patients after liver cancer liver transplantation is achieved, warning is automatically given out when a risk threshold value is reached, timely and accurate early warning information is provided for medical staff, and by collecting medicine use information and patient body function information, the patient prognosis is accurately predicted. And the physical condition of the patient can be obtained in real time through long-term monitoring, so that the prognosis prediction result is more accurate.

The invention discloses a liver transplantation post-operation intelligent management system and method based on multi-modal monitoring and AI. The method comprises the following steps that S1, physiological parameters, biomarker data, iconography data and self-reporting data of a patient are collected in real time; s2, carrying out preprocessing, feature extraction and fusion on the collected data, and predicting the postoperative complication risk of the patient by using a risk prediction model; s3, generating a personalized management strategy by using a reinforcement learning algorithm according to a risk prediction result, and providing early warning information and intervention suggestions for medical personnel and patients; s4, according to the postoperative management plan and the doctor's advice of the patient, a fixed-point medication reminding function is set, a personalized medication scheme is generated, and medication compliance of the patient is monitored; and S5, the patient makes an appointment for remote medical services, selects appropriate doctors and time to carry out video inquiry or online consultation, and records inquiry content.

The invention discloses a liver cancer post-transplantation muscle loss prediction method and device, and belongs to the technical field of biomedicine, and the method comprises the steps: constructing an unbalanced random forest model comprising a plurality of decision trees, independently predicting through the plurality of decision trees to obtain a plurality of high-risk or low-risk dichotomy prediction results, taking the proportion of the decision tree with the prediction result being high risk in all decision trees as the prediction probability of muscle loss after liver cancer liver transplantation finally output by the model; performing risk classification according to the prediction probability, and judging the postoperative muscle loss level of the patient as high risk, medium risk or low risk; constructing a decision tree model to layer prognosis of patients, and dividing the patients into a high-risk group, a medium-risk group and a low-risk group; and carrying out survival rate prediction in combination with liver transplantation standards and prognosis layering results of patients. According to the method, the muscle loss level after the liver transplantation can be accurately predicted, and a clinician can make a personalized treatment scheme and perform scientific management after the transplantation.

The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginne vasopressin (AVP), antidiuretic hormone (ADH), and agripressin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and / or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.

The invention provides a prognosis risk prediction method and device for liver cancer liver transplantation, electronic equipment and a medium, and relates to the technical field of prognosis risk prediction.The method comprises the steps that a liver cancer liver transplantation block set of a target patient is obtained; respectively inputting each liver cancer liver transplantation block in the liver cancer liver transplantation block set into the single-block liver cancer liver transplantation scoring model to obtain a liver cancer liver transplantation score corresponding to each liver cancer liver transplantation block output by the single-block liver cancer liver transplantation scoring model; determining a target liver cancer liver transplantation block according to the liver cancer liver transplantation score corresponding to each liver cancer liver transplantation block and each liver cancer liver transplantation block in the liver cancer liver transplantation block set; and inputting the target liver cancer liver transplantation block into a liver cancer liver transplantation region prognosis analysis model to obtain a liver cancer liver transplantation prognosis recurrence risk prediction result of the target patient output by the liver cancer liver transplantation region prognosis analysis model. The accuracy of risk prediction is improved based on feature structure analysis.

This invention relates to a method and application for enriching circulating tumor cells (CTCs) based on ambient temperature mechanical perfusion technology, belonging to the field of biomedical technology. The method comprises the following steps: flushing the liver resected during liver transplantation via the portal vein and hepatic artery, connecting it to an ambient temperature mechanical perfusion loop, and performing in vitro perfusion using simulated blood perfusion fluid; when perfusion exceeds 2 hours and the lactate content drops to <5 mmol / L, collecting the simulated blood perfusion fluid; and sequentially subjecting the simulated blood perfusion fluid to centrifugation, red blood cell removal, and white blood cell removal to obtain enriched circulating tumor cells (CTCs) for liver cancer. A human liver cancer ex vivo organ perfusion model is constructed using NMP technology to fully recreate the tumor microenvironment and CTC generation process, and the large volume of perfusion fluid is processed to achieve efficient enrichment of CTCs.

The present application relates to a method for inducing liver oval cell line to form functional liver-like organ tissue on a liver acellular biological scaffold, belonging to the field of biotechnology, wherein the liver oval cell line (HOCL) is used as seed stem cells, and is implanted into a regenerative liver acellular biological scaffold (R-DLS) with biological activity; according to the in-vitro simulation of the development of a body-like liver organ microenvironment concept, a conditional culture solution capable of inducing HOCL liver function differentiation and reconstructing a functional liver organ structure is added, and a functional liver-like organ tissue is constructed in an in-vitro 3D culture system. In the method, the HOCL in the R-DLS shows its differentiation into functional hepatocytes in 2-24h in the in-vitro 3D culture system, and the liver-like organ tissue can be formed in 21 days. The "new liver" constructed by the method has important clinical conversion value for being used as a liver transplantation donor and treating ESLD.

The present invention discloses a degradable stent suitable for end-to-end anastomosis of bile ducts during liver transplantation, comprising a transverse stent assembly, a longitudinal stent assembly and a periodically degradable connecting assembly, a transverse tube body, a retaining net, a connecting sleeve, an end sleeve, an air-avoiding hole, a longitudinal tube body, a periodically degradable sleeve, and a periodically degradable filling block. Firstly, the transverse stent can achieve docking of donor bile ducts and recipient bile ducts of different diameters, thereby improving matching and applicability. The longitudinal stent can facilitate in vitro communication in the early stage of catheterization, thereby facilitating drainage and perfusion. Secondly, the periodically degradable sleeve and the periodically degradable filling block can be continuously degraded by the patient's body secretions and decompose after a certain period of time, thereby eliminating the docking between the transverse stent assembly and the longitudinal stent assembly, separating them, and facilitating the disassembly and removal of the longitudinal stent assembly. Finally, the grid structure of the retaining net can facilitate the accumulation of bioadhesives, thereby achieving the blocking of the retaining net. After the longitudinal stent assembly is separated from the transverse stent assembly, the transverse tube body in the transverse stent assembly is in a sealed state.

The invention discloses a traditional Chinese and western medicine disease and syndrome combined hepatic ischemia-reperfusion injury ligand and receptor interaction communication network construction method, system and device, a medium and a product, and relates to the field of medicine. Traditional Chinese medicinal materials related to occurrence and development of the hepatic ischemia-reperfusion injury are identified from Chinese literatures and Chinese patents; constructing a traditional Chinese medicine target group based on traditional Chinese medicines; keywords are set based on pathological knowledge of western medicine, and biomarkers or target protein groups related to occurrence and development of hepatic ischemia-reperfusion injury are identified from different literatures; constructing a disease target group based on the biomarker or the target protein group; the traditional Chinese medicine target group and the disease target group form a liver transplantation HIRI target network; and performing network topology comparison on the traditional Chinese medicine target group and the disease target group to determine an optimal traditional Chinese medicine. According to the application, the advantages of combination of traditional Chinese medicine and western medicine are exerted, and the corresponding traditional Chinese medicinal materials are determined by constructing the liver transplantation HIRI target network.

The invention belongs to the technical field of information processing, and particularly relates to a liver transplantation medication guidance system based on multi-expert diagnosis opinions and intelligent reasoning. The system comprises a data management module, a diagnostic analysis module, a medication suggestion module and a feedback module, the data management module is used for collecting user health index data and diagnosis suggestions of multiple experts and storing medical literature data; the diagnostic analysis module is used for generating diagnostic information of the user according to the information of the data management module; the medication suggestion module is used for generating a medication scheme according to the information of the data management module, the diagnosis information of the user and the feedback information of the feedback module; the feedback module is used for acquiring feedback information which comprises health index data after the user takes medicine and feedback information of an expert; according to the method, the limitation of a traditional medication guidance method is overcome, and more scientific, objective and accurate liver transplantation postoperative medication guidance is realized.

The invention discloses a method, a system and equipment for predicting liver transplantation prognosis of liver cancer. The liver cancer liver transplantation prognosis prediction model construction method comprises the following steps: based on prior literature knowledge of liver cancer liver transplantation influence factors, carrying out unsupervised learning on a basic large language model to obtain an initial large language model; a data set is obtained, natural language transformation is conducted on the data set according to the cue word template, the initial large language model is trained, a pre-trained large language model is obtained, and the data set comprises clinical data of a plurality of liver transplantation patients; multi-dimensional information of typical cases in the liver transplantation patient is obtained to serve as tagged fine adjustment data, fine adjustment is conducted on the pre-trained large language model, a prediction model is obtained, and the prediction model is used for prognosis prediction of liver transplantation of liver cancer. By adopting the embodiment of the invention, the liver cancer liver transplantation prognosis prediction model with expert-level evaluation ability can be constructed, so that the accurate prediction of the prognosis of the liver cancer liver transplantation patient is realized.

The invention discloses application of a CGAS-STING signal channel inhibitor in preparation of a medicine for preventing and treating hepatic ischemia-reperfusion injury, and relates to the technical field of biological medicine. According to the application, a cGAS-STING signal channel in macrophages is inhibited by using a cGAS inhibitor or an STING inhibitor, activation of double-stranded deoxyribonucleic acid released by a neutrophile granulocyte extracellular trapping net on a DNA induction channel is blocked, and the M1 type polarization level of the macrophages is reduced. The traditional Chinese medicine composition can effectively relieve liver inflammatory response and cell apoptosis, and a new path is provided for preventing and treating acute liver injury after liver transplantation or liver resection.

The invention discloses an application of S100A9 in treatment of lung injury caused by liver ischemia reperfusion. A liver ischemia reperfusion animal model is utilized to find that S100A9 is closely related to lung injury caused by liver ischemia reperfusion. Lung injury caused by liver ischemia reperfusion can be effectively relieved by knocking out the S100A9 gene or inhibiting a downstream signal channel mediated by the S100A9. In addition, it is also found that the S100A9 expression level has very strong correlation with lung injury after liver transplantation by collecting patients clinically subjected to liver transplantation. Research results of the invention show that S100A9 is a diagnosis and treatment marker for lung injury caused by hepatic ischemia reperfusion.

The application discloses a kind of based on non-diffracting airy beam intrahepatic blood vessel three-dimensional imaging method, belong to intrahepatic blood vessel three-dimensional imaging technical field, solve the problem of insufficient accuracy and detection sensitivity of existing detection method, method includes by liver transplantation or biopsy surgery obtains liver tissue, liver tissue is fixed using 4%PFA processing, liver tissue is bleached using H2O2Solution, antigen repair is carried out to liver tissue using FLASH solution, using goat serum blocking solution to the liver tissue after antigen repair blocking treatment;Liver tissue immunostaining treatment, liver tissue dehydration treatment, based on non-diffracting airy beam and high-throughput microscope to the liver tissue after processing imaging, obtain the three-dimensional imaging picture of liver tissue;The application is immunofluorescence staining and transparent treatment to liver tissue, so that laser can smoothly penetrate tissue and carry out three-dimensional imaging, can realize single wide-range image capture.

Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and / or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.

The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy. Thus, the present invention relates to humanized anti-claudin-1 antibodies and uses thereof, in particular for the prevention and treatment of hepatitis C virus infection, virus-induced liver diseases, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy. Thus, the present invention relates to humanized anti-claudin-1 antibodies and uses thereof, in particular for the prevention and treatment of hepatitis C virus infection, virus-induced liver diseases, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy. Thus, the present invention relates to humanized anti-claudin-1 antibodies and uses thereof, in particular for the prevention and treatment of hepatitis C virus infection, virus-induced liver diseases, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

The invention discloses a degradable stent suitable for bile duct end-to-end anastomosis in liver transplantation, which comprises a transverse stent assembly, a longitudinal stent assembly, a regularly degradable connecting assembly, a transverse tube body, a baffle net, a connecting sleeve, an end sleeve, a clearance hole, a longitudinal tube body, a regularly degradable sleeve and a regularly degradable filling block, firstly, butt joint of donor biliary tracts and recipient biliary tracts with different pipe diameters can be achieved through the transverse support, the matching degree and applicability are improved, in-vitro communication and drainage and perfusion are facilitated through the longitudinal support at the initial stage of catheter indwelling, secondly, the regularly degradable sleeve and the regularly degradable filling block can be continuously degraded by secretion in the body of a patient and decomposed after a certain period of time, and the catheter indwelling effect is improved. Butt joint of the transverse stent assembly and the longitudinal stent assembly is canceled, the transverse stent assembly and the longitudinal stent assembly are separated, the longitudinal stent assembly can be detached and taken out conveniently, finally, by means of the gridding structure of the blocking net, accumulation of the biological adhesive can be facilitated, the blocking net is blocked, and after the longitudinal stent assembly and the transverse stent assembly are separated, a transverse pipe body in the transverse stent assembly is in a sealed state.

Disclosed herein are compositions and methods for inducing differentiation of an induced pluripotent stem cell (iPSC) or an embryonic stem cell (ESC) into a hepatocyte. The compositions and methods may also be used to promote maturation of a hepatocyte. The compositions and methods may include modulators of a gene selected from NHLH2, KLF7, GSC2, PPARG, SALL4, ESRRG, ESRRB, SMAD2, KLF6, TCF7, SMARCA2, SMAD3, TFEC, PURB, ZNF398, ASCL2, NFIB, ZIC4, ZNF618, FOXA2, NR5A1, FOXA3, HNF4A, HNF4G, HBP1, NHLH1, NR5A2, or YAF2, or a combination thereof, or a gene product thereof. The compositions and methods may be used for liver transplantations.

The invention discloses a multi-phase CT image-based early recurrence risk prediction method and system after hepatocellular carcinoma liver transplantation, and belongs to the technical field of medical image processing and artificial intelligence. The method comprises the following steps: S1, multi-phase CT image acquisition and standardization preprocessing; s2, sketching a tumor area and a peritumor area to form a target volume; s3, extracting radiomics features and deep learning features; s4, performing multiple rounds of feature screening, and combining clinical risk factors to construct a deep learning radiomics column graph prediction model; s5, risk prediction and layering; and S6, combining with the traditional clinical standard to realize increment value integration. The system comprises an image access and preprocessing module, a feature calculation engine, a model management module, a risk assessment module and a clinical decision support module. The problems of insufficient information utilization, difficulty in clinical integration and the like in the prior art are solved by jointly analyzing the tumor and the peritumoral region and fusing multi-dimensional features, the early recurrence prediction precision is improved, and support is provided for clinical decision making.

This invention discloses the application of PIEZO1 inhibitors in the preparation of drugs to inhibit liver regeneration. Specifically, this invention relates to the application of the PIEZO1-specific inhibitor Dooku1 in the preparation of drugs to inhibit liver regeneration after hepatectomy. This invention also provides the application of Dooku1 in the preparation of reagents for constructing animal models of liver aplastic disorder. Experiments of this invention show that administration of Dooku1 significantly reduces the liver weight / body weight ratio, inhibits hepatocyte proliferation (significantly decreasing Ki67 positivity rate), and is accompanied by an increase in serum ALT and AST levels, successfully constructing a target-specific and reproducible animal model of liver aplastic disorder. This invention is the first to apply PIEZO1 inhibitors to inhibit liver regeneration, filling the technological gap in negatively regulating liver regeneration through inhibition of the PIEZO1 pathway, and providing potential candidate drugs and intervention strategies for pathological conditions requiring inhibition of abnormal liver hyperplasia after liver transplantation and hepatectomy.

The present invention relates to: a method for differentiating stem cell-derived hepatocytes by using fasudil and gelatin; and the like. The method for differentiating stem cell-derived hepatocytes, according to the present invention, induces, by means of fasudil, the differentiation of stem cells into endoderm in an early stage of differentiation of stem cells into hepatocytes, inhibits lipid droplet formation through high-viscosity gelatin coating of a culture container, activates mitochondrial functions, up-regulates the expression of endoderm genes, and down-regulates the expression of ectoderm and mesoderm genes, thereby improving the efficiency of differentiation of stem cells into hepatoblasts. In addition, low-viscosity gelatin is added to the medium in a differentiation and maturation (late) stage so as to suppress the accumulation of lipid droplets, mitochondria are activated to improve the efficiency of differentiation of hepatoblasts into hepatocytes, and the function of differentiated hepatocytes is enhanced to improve the efficiency of differentiation of stem cells into hepatocytes. Therefore, hepatocytes obtained using the method are expected to be effectively used as a cell therapeutic agent, a transplant, and the like for treating liver diseases.

The utility model relates to medical nursing technical field in general, and more specifically relates to a kind of T tube drainage device of postoperative patient of liver transplantation, including drainage bag, drainage tube, three-way valve, T tube joint and fixer, drainage tube one end is connected with drainage bag, and the other end of drainage tube is connected with T tube joint by three-way valve, and the top of drainage bag is provided with fixer;The fixer includes female buckle and buckle, and through hole is provided on female buckle, and the through hole can be used to be connected with hook, and elastic plunger matched with through hole is provided on buckle, and elastic plunger is inserted into through hole by buckle and female buckle engagement, and it is used to clamp and fix clothes, greatly improve the fixed convenience of drainage bag, so that patients can select fixing mode according to needs, and reduce the influence on activity.T tube joint can be suitable for the connection of T tube, and the connection is firm and not easy to loosen, when it is necessary to regularly inspect drainage liquid, sampling detection can be directly carried out from the third interface of three-way valve, and the operation is convenient.

The invention discloses an organ maintenance liquid for repairing liver functions as well as a preparation method and application of the organ maintenance liquid. The feed additive comprises the following components: an oxygen-carrying component, succinyl gelatin, sodium chloride, sodium hydroxide, sodium bicarbonate, calcium gluconate, magnesium sulfate, chromium chloride, copper chloride, ferric chloride, manganese chloride, sodium molybdate, sodium selenite, zinc chloride, potassium iodide, sodium fluoride, isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, serine, valine and histidine. The injection is prepared from arginine, alanine, asparaginic acid, cysteine, glutamic acid, proline, tyrosine, glycine, sodium hydrogen sulfite, heparin, methylprednisolone sodium succinate, broad-spectrum antibiotics, antifungal drugs, FXR agonists and sterilized water for injection. The oxygen-carrying component is washed red blood cells or concentrated red blood cells or artificial blood. The viscosity of the organ maintenance liquid is closer to that of plasma, the influence on the blood coagulation function and the renal function is avoided, and the organ maintenance liquid has higher safety, can treat ischemia reperfusion injury, repair the liver biliary tract function and remarkably reduce various inflammation indexes, and is used for ischemia-free liver transplantation.

The invention provides an antioxidant nano-enzyme for liver-related diseases as well as a preparation method and application of the antioxidant nano-enzyme, and belongs to the technical field of nano-enzymes. The invention provides an antioxidant nano-enzyme. The antioxidant nano-enzyme comprises a Prussian blue nano-enzyme and / or a copper monatomic nano-enzyme. Compared with the prior art, the prussian blue nano-enzyme or the copper monatomic nano-enzyme is prepared by a simpler method and has multiple enzyme activities. The anti-oxidation nano-enzyme aims at parenchymal hepatic cells to achieve the effects of removing ROS (reactive oxygen species) in damaged hepatic cells, relieving oxidative stress damage of damaged liver parts and reducing the level of pro-inflammatory macrophages, so that inflammation-induced hepatic cell necrosis is prevented, and accurate and efficient treatment of the anti-oxidation nano-enzyme including hepatic transplantation injury and hepatic ischemia reperfusion is realized.

The invention belongs to the technical field of biological medicine, and provides application of CD93 + DC / IL-10 as a target in screening of drugs for inhibiting immunological rejection and tolerance after liver transplantation. The CD93 < + > DC inhibits CD8 < + > T cells by secreting IL-10, inhibits immunological rejection after liver transplantation and enhances tolerance. The result shows that compared with the non-rejection group, the acute rejection group has the advantages that the CD8 + T lymphocytes are increased, and the CD93 + DC is reduced. A mouse liver transplantation model experiment result shows that the number of CD8 + T lymphocytes in blood and liver of a rejection group is higher, and the CD93 + DC level is reduced. In-vitro experiments prove that the CD93 + DC can inhibit the proliferation, migration and secretion functions of CD8 + T lymphocytes. After the anti-IL-10 antibody is added, the inhibition effect of CD93 + DC on CD8 + T lymphocytes is weakened. CD93 + DC inhibits CD8 + T lymphocytes through IL-10, and plays a key role in acute rejection of liver transplantation.

The invention relates to the technical field of medical software, and discloses an intelligent follow-up visit robot system for a posthepatic transplantation transition period of children, which comprises a robot body, a communication module, and a parent terminal and a transplantation center follow-up visit system which are in communication connection with the robot body, a compliance prediction module; an ecological instantaneous evaluation module; and the ecological instantaneous intervention module is used for automatically triggering intervention measures of corresponding levels according to the follow-up state evaluation result and a preset grading intervention strategy. The ecological instantaneous evaluation module and the ecological instantaneous intervention module work cooperatively based on the same real-time data stream, so that the intervention content, the intervention opportunity and the intervention intensity can be adaptively adjusted along with the dynamic change of the medication compliance and the psychological behavior state of the child patient.

The invention belongs to the technical field of medical auxiliary instruments, and discloses blood vessel anastomosis equipment for rapid liver transplantation by magnetic assistance, the blood vessel anastomosis equipment comprises two long rods, the bottom ends of the two long rods are fixedly provided with round tubes respectively, and the outer surfaces of the round tubes are sleeved with first handles in a threaded mode. Through arrangement of a first handle, a pressing block, an extension plate, an auxiliary plate and a magnet, when the first handle is rotated, the first handle drives one end of an inclined rod to move through a built-in ring, so that the inclined rod generates thrust on a cross rod, and the cross rod is pushed to drive a vertical rod and the pressing block to move to be separated from the extension plate; at the moment, a blood vessel can penetrate through the circular tube and be turned outwards to the outer surface of the auxiliary plate, and due to the fact that the magnetic poles of the two magnets are opposite, the blood vessel located in the circular tube can be matched together under the action of the magnets, so that blood vessel matching of rapid liver transplantation can be carried out through magnetism assistance, the operation time is shortened, and the operation risk is reduced.

The invention discloses an engineering modification method for improving the repair effect of an exosome on liver injury, which is characterized in that the exosome is subjected to engineering modification, and the exosome is accurately guided to a liver area needing to be treated, so that the repair effect of the exosome on the liver injury is improved. The invention provides a new hope for patients subjected to liver surgery, especially for liver transplantation patients, and the engineered and modified mesenchymal stem cell exosome is expected to assist liver transplantation and improve prognosis of the liver transplantation patients.